Evidence map›Paper›PMID 38492020›Full record

ArticleAnnals of hematology2024

Efficacy of elotuzumab for multiple myeloma deteriorates after daratumumab: a multicenter retrospective study.

Naokazu Nakamura, Nobuyoshi Arima, Teruhito Takakuwa, Satoshi Yoshioka, Kazunori Imada, Kentaro Fukushima, Masaaki Hotta, Shin-Ichi Fuchida, Junya Kanda, Nobuhiko Uoshima and 18 more

Abstract readMulticenter Study
PubMed Publisher
In one paragraph

Article in Annals of hematology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 17 institutions in 1 country.

Naokazu NakamuraDepartment of Hematology, Shinko Hospital, 1-4-47, Wakihamacho, Chuo-Ku, Kobe, Hyogo, 651-0072, Japan. n_nakamura@kuhp.kyoto-u.ac.jp.
Nobuyoshi ArimaDepartment of Hematology, Shinko Hospital, 1-4-47, Wakihamacho, Chuo-Ku, Kobe, Hyogo, 651-0072, Japan.
Teruhito TakakuwaDepartment of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Satoshi YoshiokaDepartment of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
Kazunori ImadaDepartment of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
Kentaro FukushimaDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.
Masaaki HottaFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Shin-Ichi FuchidaDepartment of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan.
Junya KandaDepartment of Hematology and Oncology Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Nobuhiko UoshimaDepartment of Hematology, Japanese Red Cross Kyoto Daini Hospital, Kyoto, Japan.
Yuji ShimuraDivision of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Hirokazu TanakaDepartment of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osakasayama, Japan.
Kensuke OhtaHematology Ohta Clinic, Shinsaibashi, Japan.
Satoru KosugiDepartment of Internal Medicine (Hematology), Toyonaka Municipal Hospital, Toyonaka, Japan.
Hideo YagiDepartment of Hematology and Oncology, Nara Prefecture General Medical Center, Nara, Japan.
Satoshi YoshiharaDivision of Hematology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
Ryosuke YamamuraDepartment of Hematology, Osaka Saiseikai Nakatsu Hospital, Nakatsu, Japan.
Yoko AdachiDepartment of Internal Medicine, JCHO Kobe Central Hospital, Kobe, Japan.
Hitoshi HanamotoDepartment of Hematology, Kindai University Nara Hospital, Nara, Japan.
Hirohiko ShibayamaDepartment of Hematology, National Hospital Organization Osaka National Hospital, Osaka, Japan.
Naoki HosenDepartment of Hematology and Oncology, Osaka University Graduate School of Medicine, Suita, Japan.
Tomoki ItoFirst Department of Internal Medicine, Kansai Medical University, Hirakata, Japan.
Chihiro ShimazakiDepartment of Hematology, Japan Community Health Care Organization Kyoto Kuramaguchi Medical Center, Kyoto, Japan.
Akifumi Takaori-KondoDepartment of Hematology and Oncology Graduate School of Medicine, Kyoto University, Kyoto, Japan.
Junya KurodaDivision of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Itaru MatsumuraDepartment of Hematology and Rheumatology, Faculty of Medicine, Kindai University, Osakasayama, Japan.
Masayuki HinoDepartment of Hematology, Osaka Metropolitan University Graduate School of Medicine, Osaka, Japan.
Kansai Myeloma Forum
Kindai University · JPKansai Medical University · JPKyoto Medical Center · JPKyoto Prefectural University of Medicine · JPKyoto University · JPOsaka Hospital · JPOsaka University · JPShinko Hospital · JPHyogo Medical University · JPJapanese Red Cross Society Kyoto Daini Hospital · JPKobe Central Hospital · JPNara Medical University · JPOsaka Metropolitan UniversityOsaka National Hospital · JPSaiseikai Nakatsu Hospital · JPTokyo Metropolitan University · JPToyonaka Municipal Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Elotuzumab-based regimens are sometimes selected for multiple myeloma treatment after daratumumab-based regimens. However, there has been insufficient discussion on the efficacy of elotuzumab after daratumumab. We used Kansai Myeloma Forum registration data in a multicenter retrospective evaluation of the efficacy of elotuzumab after daratumumab. Overall survival (OS) rate and time to next treatment (TTNT) were significantly worse in the cohort given elotuzumab after daratumumab (Dara cohort, n = 47) than in the cohort with no history of daratumumab administration before elotuzumab (No-Dara cohort, n = 80, OS: P = 0.03; TTNT: P = 0.02; best response: P < 0.01). In the Dara cohort, OS and TTNT rates were worse with sequential elotuzumab use after daratumumab than with non-sequential (OS: P = 0.02; TTNT: P = 0.03). In patients given elotuzumab < 180 days after daratumumab, OS (P = 0.08) and best response (P = 0.21) tended to be worse, and TTNT was significantly worse (P = 0.01), than in those given elotuzumab after ≥ 180 days. These findings were confirmed by subgroup analyses and multivariate analyses. Monoclonal-antibody-free treatment might be preferable after daratumumab-based regimens. If possible, elotuzumab-based regimens should be considered only ≥ 180 days after daratumumab use.

Indexed as

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedMultiple MyelomaAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsFemaleHumansMaleMiddle AgedRetrospective StudiesSurvival RateTreatment OutcomeAntibodies, MonoclonalAntibodies, Monoclonal, HumanizeddaratumumabelotuzumabDaratumumabElotuzumabImmune microenvironmentMultiple myeloma

Identifiers

PMID38492020
OpenAlexW4392880834

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.